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Patients were classified according to their
PMN counts in VSAA, SAA and NSAA (see
table 1), and the availability of an HLA-
identical donor. After a minimal observation
time of two weeks in VSAA and 6 weeks
in NSAA, those with an available HLA-
identical family donor were prepared
for SCT, while the rest received combined
immunosuppressive therapy.
Thirty five centers in Germany
and Austria participated in this stUdy. A total
of 122 children with neWly diagnosed SAA
according to the CAMITTA criteria [8] were
investigated between November 1993
and June 1998. Children with congenital
disorders (e.g. FANCONI-anemia) or pre-
vious treatments were excluded. The dia-
gnosis of SAA was based on bone marrow
biopsy in all cases. In addition, conventional
cytogenetics was performed in 87 patients,
as well as interphase in situ hybridisation
(FISH) for the detection of monosomy
7 or trisomy was carried out 8 in 46 pa-
tients.
DIAGNOSTIC
STUDY DESIGN (fig. 1) .
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Fig. 1. Study design of SAA94 pilot protocol.
PATIENTS AND
PROCEDURES
Severe aplastic anemia (SAA) was one of
the first indications for stem cell tran-
splantation (SCT) with the aim of to repo-
pulating an empty marrow by healthy
allogeneic stem cells. In 1972, the first
successful engraftment of bone marrow
stem cells in SAA was carried out in Seattle
(USA) [1]. In Germany (Munich) [2] and
Poland (Poznan) [3] the first engraftments
were made in 1975 and 1982, respectively.
Since then, however, the indication for SCT
in SAA has relatively decreased, as shown
by Gratwohl et al. [4], from 25 % in 1973
to 5 % in 1997, compared with the increase
in leukemias from 13 % to 79 %, over
the same period of time.
Though results in alternative - mainly
combined immunosuppressive - therapy
(1ST) for SAA have also distinctly improved,
SCT remains the first option in children and
young adults who have an available HLA-
identical sibling as a donor. In the last
20 years survival after SCT for SAA
increased from 52 % to 78 % [5].
In children, survival rates as high as 85 %
or more in some centers have been
reported [6]. This success was due to more
effective conditioning, GVHD prophylaxis
and supportive care. The main problems
that still remain are graft rejection and -
to a lesser degree- chronic GVHD.
Results from donors other than HLA-
identical siblings have so far been less
encouraging. That is why this therapeutic
option is considered as second line
treatment for children who do not respond
to immunosuppressive therapy.
In 1994, a prospective multicentric
German-Austrian stUdy was started
to standardize treatment for SAA in chil-
}dren, and to compare results of SCT
and 1ST [7]. In this report current results will
be shortly summarised.
Proceedings of the Conference "Haematopoietic Stem Cell Transplantation in Children. Current Status,
Controversies and Perspectives", Poznan, 16 -17 December 1999.
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SeT-GROUP
37/122 patients had an HLA-identical
family donor. All but two (donor not
available, refusal of parents) underwent
primary SCT. Conditioning therapy
consisted of 50mg/kg/d cyclophosphamide
for a total dose of 200 mg/kg in one
untransfused patient. All others received in
addition ATG (horse, LTD. Merieux)
0.75 ml/kg/d. (approximately 15 mg/kg/d)
for 4 days. Unmanipulated bone marrow
stem cells were given 24 h after the last
dose. GVHD prophylaxis consisted of cyclo-
sporine A (CSA) and a short course
of methotrexate (MTX) (15 mg/m2 Id +1,
10 mg 2 /d + 3, +6, +11) CSA dosage was
adjusted to their blood levels and was
discontinued after d+ 100, except in case
of GVHD or mixed chimerism.
1ST GROUP
The remaining 87 patients received
combined immunosuppressive treatment
consisting of ATG (horse; Ltd Merieux)
0.75 ml/kg/d (approximately 15 mg/kg/d ) for
8 days. For prophylaxis of acute adverse
allergic reactions and serum sickness
prednisolone 1 mg/kg/d was given
for 28 days and then discontinued.
In addition, all patients received CSA
5 mg/kg/d, adjusted to their blood levels
orally for at least 6 months. In VSAA
and SAA, G-CSF (filgrastim Ltd AMGEN )
was given in a dosage of 5 jig/kg/d
from day 1 to day 28, and then increased
to 10 jig/kg/. until day 56 in case
of continuous PMN counts below 1.5 GIl.
In responders, G-CSF was tapered
off the same dose being given with
increasing intervals. Response criteria
are shown in table 2.
Tab. 2.
Immunosuppressive therapy (1ST)
Response criteria
Complete Response (CR)
Hb> 12g/dl
PMN>0.5G11
platelets> 100 GIl
Partial Response (PR)
PMN >0.5G/l
reticulozytes > 30 GIl
transfusion independency
Sale PMN-Response to G-CSF
PMN > 0.5 GIl
transfusion dependency of platelets
andlor red cells
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SUPPORTIVE THERAPY
All patients were transfused with
leukocyte depleted irradiated (With 20 Gy)
and CMV -lgG - negative blood products.
Routine antifungal prophylaxis consisted
of oral itraconazol and inhalation with
an amphotericin B solution. Fever patients
received intravenous broad spectrum anti-
biotics, non-absorbable antibiotics were not
given. During periods of severe neutropenia
reverse isolation and strict hand desin-
fection were recommended.
STATISTICS
Kaplan-Meier plots were used to calculate
the actuarial probability of survival, the pro-
babilityof relapse and that of clonal disease,
and the kinetics of response. The logrank
test was used for comparison of Kaplan-
Meier curves. Contingency tables,
CHI-square test and Fisher's exact test were
used to investigate possible risk factors.
PATIENT CHARACTERISTICS
In 9 children the disease was associated
with eareier hepatitis (1 hepatitis B, 1 hepa-
titis C, 7 with elevated transaminases, but
negative for hepatitis A, B, C). All other
cases must be classified as "idiopathic".
The median age of the whole group was
9.5 y. (0.9 - 16.9 y.) There was a slight, but
not significant difference in age, gender,
severity of SAA and interval between
diagnosis and treatment between the two
groups treated with SeT and 1ST resp. (see
table 3).
Tab. 1.
Criteria in SAA (according to Camilla (8))
VSAA (= very severe aplastic anemia)
PMN count < 0.2 GIl
SAA (= severe aplastic anemia)
PMN count < 0.5 GIl
NSAA (= non severe aplastic anemia)
PMN count> 0.5 Gil
OVERALL SURVIVAL
Probability of survival of both groups
were comparable in children treated with
SCT (86 %) and 1ST (85 %), resp. eclively
(see fig. 2).
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Fig. 3. Probability of relapse after 1ST.
reached GR at day 112, 29 patients (34 %)
at day 180. 61 patients (72 %) were
transfusion-independent at this time.
At 18 months 35 (47 %) of the evaluable
75 patients reached GR, 54 (75 %) were
free of transfusion. Unexpectedly, patients
with VSAA showed the best response
to 1ST. After 12 months 42 of 50 children
with VSAA showed transfusion indepen-
dency, and 26 of them (52 %) achiered
complete response.
Twenty - four patients were still tran-
sfusion dependent at day 112, but
responded with their PMN counts. Only four
patients did not achieve PMN counts above
500 Gil though high doses of G-GSF,
all of them died from severe infection. A trial
of the second immunosuppressive tre-
atment in four patients (in three cases with
ATG and, in one patient with cyclo-
phosphamide ) was not successful, all
of them remained transfusion dependent.
In addition to non-response, main
problems in the 1ST-group were relapse and
evolution of a clonal disease. Seventeen
of the 72 responders relapsed, the pro-
bability of relapse being 28 % after
67 months (see fig. 3). Nine patients
achieved a second response after re-
induction of GSA.
In 13 patients, a clonal disease developed
2 - 35 months after beginning of 1ST with
a probability of 18 % at 67 months.
Four patients progressed to AML, four
to MDS after partial or complete response
to 1ST. In the remaining 5 patients
chromosomal abnormalities were observed
without evidence of malignant evolution
(fig. 4)
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Fig. 2. Probability of survival after 1ST and BMT.
PRIMARY SeT
Thirty of 35 children undergoing primary
SGT survived. Thirty - three were grafted
from their HLA-identical siblings, one from
her identical twin, and one girl from her
phenotypical identical father. The median
cell dosage was 3.14 x 108 mononuclear
cells Ikg (1.3-5.4 x 108mononuclear cells Ikg
), two children (6 % ) died early after
transplant, one of aspergillosis, the other
from heart failure. Twenty -six evaluable
patients showed stable engraftment. Five
patients (15 %) rejected the graft
1 - 49 months (median 6 months ) after
SGT, one of those having been successfully
regrafted. Two children died from severe
GVHD after 2nd or 3rd SGT resp.
The remaining two patients showed
autologous recovery when treated with GSA
and G-GSF. There was no difference
in age, number of previously given blood
products or interval between diagnosis and
SGT between the successfully grafted
patients and those who rejected the graft.
Severe acute GVHD grade IV occurred
in two patients, one of them - the girl grafted
from her father - died from extended chronic
GVHD and recurrent pneumonia. The other
patient developed chronic GVHD involving
the liver and gut. With his liver and gut
problems resolved, he now suffers from
a chronic lung disease, and still needs
immunosuppressive treatment. The median
age at diagnosis was significantly lower
(p < 0.01) in surviving patients (n =30,
median 8.8 y., range 2.2-15.8 y. vs n= 5,
median 15 y. ,range 10.3 -15.4 y.)
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SECONDARY SeT
defined for participants in the study.
The recommended regimen, according
to the protocol used in SEATTLE (9),
consisting of low dose TBI (2 x 2 Gy),
cyclophosphamide (200 mg/kg) and ATG
was employed in three patients, all of them
survive.
The remaining patients received various
regimens depending on the status
of the disease, HLA-incompatibility
of a donor or manipulation of the graft.
Seven patients were irradiated with higher
TBI- doses (7.5 - 12 Gy), partly in combi-
nation with T-Cell- depletion ( n = 1 ) or CD
34 positive stem cell selection (n = 3).
Two children with MDS and monosomy
7 received Busulfan- based regimens.
Two patients grafted from their haplo-
identical parents died after successful
engraftment from severe virus infection
(1 from CMV, 1 from EBV); two further
patients died, one after graft failure from
apergillosis and, the other from acute lung
emboly after 10 .months. Though a total
of 8 patients survived, there were distinctly
more complications in SCT from alternative
donors compared with the situation in HLA-
sibling donors.
n= 87
p = 0,18
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Fig. 4. Probality of clonal disease after 1ST.
Thirteen patients received secondary SCT
because of the failure of 1ST (n= 7), therapy
resistant relapse (n = 3) and / or clonal
disease ( 1 AML, 2 MDS ). One child was
grafted from HLA-id. sibling , the other
12 from alternative stem cell donors;
4 / 12 received stem cells from family do-
nors, one from a phenotypical identical
aunt, one from HLA-1 Ag-mismatched mo-
ther, and two from haplo-identical parents.
The remaining 8 patients were grafted from
HLA-identical unrelated donors. The median
interval from diagnosis to SCT was
22 months (range 10 - 45 months).
A conditioning regimen was not strictly
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Tab. 3. Clinical characteristics of 122 children with aplastic anemia.
All BMT 1ST
Number of patients
122 35 87
Median age (range) (yrs) 9.5 10.0 9.1(0.9·16.9) (2.2·15.8) (0.9 - 16.9)
Sex: male / female
67/55 14/21 53/34
Severity VSAA 70 18 52
SAA 43 15 28
NSAA 9 2 7
Median duration (range) 28 48 23(3 - 272) 12-272 (3-168)
DISCUSSION
Results in SCT from HLA-id. sibling
donors have essentially been improved over
the last decade, especially in young patients
with SAA. [10]. This success
is mainly due to better supportive care
and decreased incidence of acute
and chronic GVHD [10]. In our reported
series only two adolescent patients suffered
from severe Gr IV acute GVHD followed
from chronic GVHD
In addition, the dominating problem of graft
rejection in pattents with SAA could be si-
gnificantly reduced, though there is still
a rate of about 10 % in all reported studies
[11]. In our patients a rejection rate of 15 %
was observed, in two of them with a fatal
outcome after repeated SCT. In case of late
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rejection a second course of CSA may
be attempted.
Thus, for primary SCT the combination
of cyclophosphamide and ATG seems
to be an optimal regimen, with radiotherapy
avoided to reduce the risk of a second
malignancy [12].
Beside secondary malignancy, late effects
after SCT seem to be rare with the ex-
ception of the sequelae of chronic GVHD. In
our earlier patients we observed an incre-
ased risk of a progressive lung disease [13].
In the cases presented here, the patient
with chronic GVD suffers from deteriorating
bronchiolitis obliterans.
Most children with SAA, however, lack
an available sibling donor; in our series 86/
122 ( 70 % ). In this situation a combined
immunosuppressive therapy is recommen-
ded
[14]. Results of 1ST could also be improved
due to a better supportive care and possibly
due to early administration of G-CSF. In our
patients, the overall response was 77 %,
and was even better in VSAA, which
contradicts the earlier results of Locasciulli
et al. [15]. As survival in both treatment
strategies- SCT or IST- are comparable,
there is already discussion under way
whether 1ST should be preferred as a front
line therapy [16].
However, two problems in 1ST remain
unresolyed: the high rate of relapse and
the risk of a clonal disease, already
observed by Speck and his group 1990 [17]
The role of G- CSF in the evolution
of a clonal disease, especially monosomy
7 remains controversial [18] Careful
diagnostic procedures are essential
at the beginning of the disease to rule out
other causes of aplasia (e.g. hypoplastic
MDS). Regular screening - especially
for monosomy 7 - is necessary in the co-
urse of SAA after 1ST. So far, no clonal
diseases of myeloid origin have been
observed after SCT [12].
Results from alternative donors in SAA
are far worse than these from HLA- id.
siblings. In 1999, J.Hows reported survival
rates of 40% in SCT from unrelated donors
and 45 % from alternative family donors
at 3 y, based on various registry data [19].
A better survival of 54 % was reported by
Margolis et al [20] in children and young
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adults when a very intensive conditioning
regimen was need including FTBI with
12-14 Gy. The best results were achieved
in two Japanese reports with higher than
80 % survival rate in smaller series of
children [21, 22].
In our study, secondary SCT from
alternative donors was recommended
urgently in cases of non-response to G-CSF
with granUlocyte counts., in a manifest
clonal disease, continuous transfusion
dependency or therapy resistant relapse.
In the latter cases, the decision for SCT was
often delayed as the quality of life in those
patients was frequently rather good. Thus,
the interval from diagnosis to SCT varied
considerably. A conditioning regimen was
not strictly defined. In cases of AMU MDS
a more intensive regimen were used.
Comparable results were achieved
in patients conditioned with low dose FTBI
and cyclophosphamide and those
conditioned with higher doses of irradiation
and T-cell depletion of the graft or CD 34
selected stem cells). The two children
transplanted from their haplo-id. parents
died from infection.
Possibly, we would have achieved better
results and fewer complications, if SCT had
been performed earlier in the course of the
disease. Second trials with common
immunosuppressants had been not
successful in our patients.
In summary, SCT is the best option
for children with SAA , if an HLA-id. sibling
as a donor is available. In the remaining
children a combined immunosuppressive
treatment should be given with careful
monitoring of a clonal disease. There
is enough evidence that ATG and
cyclophosphamide are an acceptable
conditioning regimen for children with
an HLA- id. sibling as a donor. The addition
of irradiation seems to be necessary
in the cases of an alternative donor, the role
of T-cell depletion has not yet been clearly
defined. The prognosis for children with
resistant SAA without an suitable donor
remains grave, SCT from an haplo-id donor
seems to be no successful alternative.
It may be that the development of new
potent immunosuppressive drugs is a pers-
pective for those patients.
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